{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:29:52Z","timestamp":1787776192907,"version":"build-2784847793"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"8","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Recommendations for clinical management of women with germline pathogenic variants (PVs) in breast cancer susceptibility genes vary by gene. The goal of this study was to examine the utilization of risk-reducing strategies and treatments in women with germline PVs in breast cancer susceptibility genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This cross-sectional study identified women with a PV in at least one of 13 breast cancer susceptibility genes from germline panel testing at a single commercial laboratory between 2015 and 2023. Paired health care claims data for 12 months after genetic testing were evaluated to estimate the utilization of risk-reducing mastectomy and salpingo-oophorectomy, breast magnetic resonance imaging (MRI), and pancreatic screening (magnetic resonance cholangiopancreatography or endoscopic ultrasound) in these women. Multivariable logistic regression models were used to evaluate the association of clinicodemographic factors and genetic testing results with intervention utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 3,959 women with a PV (2,088 cancer-free; 1,871 with primary breast cancer diagnosed \u2264120 days before genetic testing), the average age at testing was 45 years, 67% were White, and 90% reported a family history of cancer. Breast MRI was used by 33% of cancer-free women and 31% of women with breast cancer after genetic testing; pancreatic screening occurred in &lt;11% of the eligible population. Women with PVs in\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      versus other breast cancer susceptibility genes had higher odds of risk-reducing mastectomy (cancer-free: odds ratio 7.2 [95% CI, 3.5 to 14.5]; with cancer: 6.0 [95% CI, 4.2 to 8.5]) and salpingo-oophorectomy (cancer-free: 7.2 (95% CI, 4.6 to 11.3]; with cancer: 13.8 [95% CI, 9.7 to 19.7]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Utilization of risk-reducing surgery was highest in women with\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      PV. Pancreatic screening was low in all patients. Future studies are needed to examine the factors underlying these trends.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-26-00373","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:59:06Z","timestamp":1787774346000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Risk-Reducing Interventions in Women With Pathogenic Variants in Breast Cancer Susceptibility Genes"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-0310","authenticated-orcid":true,"given":"Emily M.","family":"Russell","sequence":"first","affiliation":[{"name":"Labcorp, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-6393","authenticated-orcid":true,"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Labcorp, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2287-1635","authenticated-orcid":true,"given":"Rachel E.","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-9175","authenticated-orcid":true,"given":"Heidi","family":"Chwan Ko","sequence":"additional","affiliation":[{"name":"Labcorp, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-9120","authenticated-orcid":true,"given":"Rebecca A.","family":"Previs","sequence":"additional","affiliation":[{"name":"Labcorp, Durham, NC"},{"name":"Department of Obstetrics &amp; Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Pineda-Alvarez","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-3756","authenticated-orcid":true,"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[{"name":"Invitae Corporation, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4084-6484","authenticated-orcid":true,"given":"Kevin","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Oncologic &amp; Endocrine Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-0143","authenticated-orcid":true,"given":"Stacy W.","family":"Gray","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-3734","authenticated-orcid":true,"given":"Nadine M.","family":"Tung","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6175-9470","authenticated-orcid":true,"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Departments of Medicine and of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2026","author":"National Comprehensive Cancer Network","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2026. https:\/\/www.nccn.org"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00299"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae074"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102702"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7011"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00425-3"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319352"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05699-y"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6400"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08889-6"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54447"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-15793-w"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.10.001"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5162"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14394-3"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-5057-7"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6937"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.4770"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0658"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2541090953"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2021.12.001"},{"key":"e_1_3_6_23_2","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High-Risk Assessment: Breast Cancer, Version 3.2026","author":"National Comprehensive Cancer Network","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Genetic\/Familial High-Risk Assessment: Breast Cancer, Version 3.2026. https:\/\/www.nccn.org"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004364"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2012.06.005"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.2031"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.5079"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70321"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2953"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8030313"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001746"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000545018"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:59:08Z","timestamp":1787774348000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1200\/PO-26-00373"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00373","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600373"}}